Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA as it expects Q4 to be “the strongest” in company history

Alvotech (ALVO) expects Q4 to be its strongest quarter, targeting $650M-$700M in revenue and $180M-$220M in EBITDA for the year. The company's guidance reflects anticipated growth and performance improvements.

Original reporting
Published Nov 12, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA as it expects Q4 to be “the strongest” in company history — source image
Decision brief

The 30-second read

$ALVOBearishMed
01

Why it matters

The guidance signals a significant improvement over prior expectations, potentially driving share price higher.

02

Market read

New revenue and EBITDA targets provide fresh valuation data for traders.

03

What to watch

Potential regulatory delays or trial setbacks could temper upside.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Alvotech is an Icelandic biotech focused on biosimilar development, listed on Nasdaq under ALVO.

Company-level read

Ticker impact

$ALVOBearishHigh confidence
Context

Alvotech disclosed its 2026 revenue target of $650M-$700M and EBITDA of $180M-$220M, indicating a strong Q4 outlook.

Expected impact

likely upward pressure as investors price in stronger earnings outlook

Evidence & confidence

New guidance is material and not previously reported, providing fresh information for valuation.

Market effects

Biotech sector may see modest lift from Alvotech's strong guidance.

Nordic biotech exposure gains attention in US markets.

Limited to biotech investors; no broad market effect.

Counterpoint

Guidance may be overly optimistic given clinical trial risks.

Key entities

  • Alvotech

    Biotech firm providing the guidance.

Related articles

$ALVOMed

Alvotech (ALVO) Q3 2026 Earnings Call Transcript

Alvotech (ALVO) reported Q3 2026 earnings, highlighting FDA approvals, strong revenue growth, and strategic partnerships. Revenue for the first 9 months was $323 million, with EBITDA of $78 million, up 15% year-over-year. The company expects Q4 to be its strongest quarter and anticipates performance to trend towards the lower end of its stated range.

$ALVOMed

What Alvotech (ALVO) Said on Its Q3 Earnings Call

Alvotech (ALVO) reported Q3 revenue down 23% YoY, citing production delays and licensing timing. Adjusted EBITDA rose 15% to $78M. CEO maintained guidance despite delayed approvals. FDA approved manufacturing changes, doubling capacity. Cash fell to $61M due to working capital. Company expects Q4 cash-flow positivity and 2027 EBITDA improvement.

$ALVOHighAI 8/10

Alvotech (ALVO): Financial results for 9M

Alvotech (ALVO) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing i